We are live on ! Find out more

AngioDynamics

ANGO

Market cap $479M

11.40 USD

-0.12

1.04%

At close Updated Oct 12, 4:00 PM EDT

Pre-market

After hours

11.43

+0.03

0.26%

1 day

-1.04%

5 days

-26.97%

1 month

-26.5%

3 months

-10.8%

6 months

11.33%

Year to date

-10.09%

1 year

2.43%

5 years

-56.02%

10 years

-33.49%

About: AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device has Peripheral Products (Interventional Devices), Ports, and Microwave Ablation. Geographically operates in the USA and Other countries; maximum revenue from the USA.

Employees: 632

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 59.1%

Negative 13.6%

Zacks Investment Research

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

AngioDynamics Stock Is Falling Thursday: What's Going On?

AngioDynamics Inc. (NASDAQ:ANGO) stock plunged more than 21% Thursday despite reporting better-than-expected first-quarter financial results.

AngioDynamics Stock Is Falling Thursday: What's Going On?

AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript

The Motley Fool

Why AngioDynamics Crashed Today

AngioDynamics beat on both top and bottom lines this morning. The company still lost $0.04 per share, pro forma, and its GAAP loss was four times bigger.

Why AngioDynamics Crashed Today

AngioDynamics Q1 Earnings Call Highlights

AngioDynamics NASDAQ: ANGO reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year outlook and announced that Eric Honroth will become president and chief executive officer effective Nov. 2.

AngioDynamics Q1 Earnings Call Highlights

Zacks Investment Research

AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates

AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.

AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2027, which ended August 31, 2026. Fiscal Year 2027 First Quarter Financial Highlights Quarter Ended August 31, 2026 YoY Growth Net Sales $80.9 million.

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Eric Honroth as President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026. Mr. Honroth will succeed Jim Clemmer, who will depart the Board on N.

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Dr. Jonathan Alis, Dr. Seth I. Sokol and their team at Jacobi Hospital in Bronx, New York have been selected as an ALPHA-PE Research Fund award recipients. The independent, investigator-led study, supported in partnership with The PERT C.

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To pa.

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

See News Rankings

Price charts implemented using Lightweight Charts™